Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients

Table 3 Associations between plasma calprotectin and functional outcome

	Model	3-month GOSE < 5 (n = 59)
		OR^ab	CI	p
Calprotectin day 0	1	1.01	0.75–1.38	0.93
Calprotectin day 0	2	0.98	0.70–1.36	0.88
Calprotectin day 7	1	1.94	1.29–2.93	0.002
Calprotectin day 7	2	2.79	1.51–4.89	0.001
Increasing calprotectin day 0–day 7	1	2.46	1.11–5.46	0.027
Increasing calprotectin day 0–day 7	2	2.53	1.07–6.10	0.036

Binary logistic regression model
Adjustment models: Model 1: unadjusted. Model 2: adjusted for age, sex, BMI, hypertension, smoking and creatinine
GOSE Glasgow Outcome Scale Extended
^aOdds ratio (OR) expressed per 1 Standard deviation (SD) increase in calprotectin
^bOR for outcomes in patients with increasing calprotectin levels from day 0 to day 7

ISSN: 2052-0492